TBPH Theravance Biopharma Inc Gross Profit Rate

Strategic alliances with industry behemoths to bring respiratory products to market establish the foundation for growth at Theravance Biopharma (TBPH). The gross sales margin illustrates production efficiency, while the 94.40 metric indicates profitability status. This model provides resilience against economic downturns, and stable demand for inhalation drugs guarantees a reliable stream of royalties from partners.
Analytical breakdowns and data insights for company Theravance Biopharma, Inc. (TBPH)

Gross margin measures the efficiency of direct production, determining the profit share after deducting all variable costs associated with product creation. The current value of 94.40, represented by the average gross margin, confirms the high profitability of Theravance Biopharma (TBPH), which is sustained by the planned capacity utilization of respiratory complexes and the continuous technological upgrading of sterile lines to comply with stringent industry standards.